An authenticable and machine readable coating for pills, tablets and other ingestible materials is provided. The disclosure also relates to methods of authenticating the same. The coatings are formed from a lattice of particles stacked to cause selective diffraction such that each pill or tablet has an optical signature. The signature associated with each coating can be read and authenticated. In one embodiment, the particles are substantially spherical and self-organized. In one embodiment, generally recognized as safe (GRAS) materials are used to form the particles.

Systems and methods of fabricating a customized dose using a medication 3D printer are provided. According to one embodiment, a system is provided that includes a 3D printer that receives prescription dose instructions from a computer or mobile communication device via a network and assembles a customized medication dose according to the prescription dose instructions by selective application of materials stored in a medicament compound container having at least one reservoir containing the materials for assembly. The materials for assembly can be provided to the 3D printer by a master conduit connecting reservoirs in the medicament compound container to the 3D printer. The 3D printer accesses specified amounts of the materials, which include medicament compounds, via the master conduit, and assembles the customized medication dose according to the prescription dose instructions.

The invention provides a method of producing a solid material, and the method includes: applying a light coloring substance to at least one of an inner surface of a die bore, an upper end surface of a lower punch, and a lower end surface of an upper punch; filling a powdery material in the die bore; compression molding the powdery material filled in the die bore with use of the upper punch and the lower punch; and irradiating with light a molded product obtained by the compression molding to color the molded product.

The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.

A solid dosage form for active ingredient release can be a preparation for medical, dental or cosmetic purposes, and is preferably a tablet. The solid dosage form comprises a three-dimensional base body which comprises an active ingredient. The solid dosage form further comprises a portion having a structure forming a two-dimensional identifier, such as, for instance, a QR code.

The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

An animal treat composition for the oral administration of a medication to an animal is disclosed. The animal treat composition comprises an adhesive portion core and an outer portion. The adhesive portion adheres to oral medication inserted into the adhesive core of the treat for administration of the medication to an animal.

The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.

The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.